17 / 21
Page 47
Volume 3
Journal of Pharmacology and Medicinal Chemistry
Nanomedicine 2019
Biotechnology 2019
May 20-21, 2019
May 20-21, 2019 London, UK
4
th
World Biotechnology CONGRESS
Nanomedicine and Nanotechnology
4
th
International Conference on
&
Development of a novel multifunctional bioglass-based coating for the next generation
of prostheses
Angela Bejarano-Villafuerte
Promethean Particles Ltd, UK
P
romethean Particles is a UK-based SME that designs and develops inorganic nanomaterials in liquid dispersions. The
company’s technology is based on a patented reactor design that allows truly continuous hydrothermal (or solvothermal)
synthesis of inorganic nanoparticles [1]. Promethean use small scale reactor systems for rapid prototyping to tune the optimum
product for each application and backs this up with pilot-scale production facilities, as well as a multi-ton scale nanoparticle
manufacturing plant (capacity more than 1000 tons per year), see figure 1.a. Our unique production process allows us to tailor
the nanoparticles to get the best functionality for an end use application. Innovation is a large focus of our business, as a direct
outcome of our R&D activities. We are currently active partners in three Innovate UKfunded projects and four EU-funded
Horizon 2020 projects. One of our Innovate UK projects aims to develop a novel multifunctional bioglassbased coating for the
next generation of prostheses. The cost of implant failure can be massive, both financially for medical services (€ 800 m/year in
Europe alone in 2010 for dental implants) and personally to the patient where amputations can be life altering. Bioglass-based
coatings can help bone integration of the implant and reduce these costly infections from occurring.
Due to the versatility of our lab-scale technology, we are able to tailor bioglass-based materials using different components and
with dopants such as ZnO and Cu. We have achieved excellent control over the ratio of components, the particle size within an
amorphous matrix (see figure 1.b-c) and the solid phase. Further tests have been performed by our partners Johnson Matthey
(JM) and Queen’s Mary University London (QMUL). Our bioglass-based materials are used by JM to coat substrates which are
then tested by QMUL to investigate their biocompatibility and antimicrobial properties. Within this project, our Bioglass-based
materials are demonstrating promising antimicrobial activities.
angela.bejarano@proparticles.co.ukJ Pharmacol Med Cheml, Volume 3